van den Born J, Gunnarsson K, Bakker M A, Kjellén L, Kusche-Gullberg M, Maccarana M, Berden J H, Lindahl U
Division of Nephrology, University Hospital St. Radboud, Nijmegen, The Netherlands.
J Biol Chem. 1995 Dec 29;270(52):31303-9. doi: 10.1074/jbc.270.52.31303.
Immunohistochemical application of antibodies against heparan sulfate proteoglycan core protein and heparitinase-digested heparan sulfate stubs showed the presence of heparan sulfate proteoglycan in all basement membranes of the rat kidney. However, a monoclonal antibody (JM-403) against native heparan sulfate (van den Born, J., van den Heuvel, L. P. W. J., Bakker, M. A. H., Veerkamp, J. H., Assmann, K. J. M., and Berden, J. H. M. (1992) Kidney Int. 41, 115-123) largely failed to stain tubular basement membranes, suggesting the presence of heparan sulfate chains lacking the specific JM-403 epitope. Heparan sulfate preparations from various sources differed markedly with regard to JM-403 binding, as demonstrated by liquid phase inhibition in enzyme-linked immunosorbent assay, the interaction decreasing with increasing sulfate contents of the polysaccharide. Mapping of the JM-403 epitope indicated that it was dominated by one or more N-unsubstituted glucosamine unit(s), since treatments that destroyed or altered the structure of such units in heparan sulfate preparations (cleavage at N-unsubstituted glucosamine units with HNO2 at pH 3.9 and N-acetylation with acetic anhydride, respectively), abolished antibody binding. Conversely, immunoreactivity could be induced in a (D-glucuronyl-1,4-N-acetyl-D-glucosaminyl-1,4) polysaccharide by the generation of N-unsubstituted glucosamine N-unsubstituted glucosamine in a JM-403-binding heparan sulfate (preparation HS-II from human aorta) was demonstrated by an approximately 3-fold reduction in molecular size following HNO2 (pH 3.9) treatment. Further characterization of the epitope recognized by JM-403, based on enzyme-linked immunosorbent assay inhibition tests with chemically/enzymatically modified polysaccharides, indicated that one or more N-sulfated glucosamine units are invariable present, whereas L-iduronic acid and O-sulfate residues appear to inhibit JM-403 reactivity. It is concluded that the epitope contains one or more N-unsubstituted glucosamine and D-glucuronic acid units and is located in a region of the heparan sulfate chain composed of mixed N-sulfated and N-acetylated disaccharide units.
针对硫酸乙酰肝素蛋白聚糖核心蛋白和肝素酶消化后的硫酸乙酰肝素短链的抗体进行免疫组织化学应用,结果显示大鼠肾脏所有基底膜中均存在硫酸乙酰肝素蛋白聚糖。然而,一种针对天然硫酸乙酰肝素的单克隆抗体(JM - 403)(van den Born, J., van den Heuvel, L. P. W. J., Bakker, M. A. H., Veerkamp, J. H., Assmann, K. J. M., and Berden, J. H. M. (1992) Kidney Int. 41, 115 - 123)在很大程度上未能对肾小管基底膜进行染色,这表明存在缺乏特定JM - 403表位的硫酸乙酰肝素链。通过酶联免疫吸附测定中的液相抑制实验表明,来自不同来源的硫酸乙酰肝素制剂在JM - 403结合方面存在显著差异,随着多糖硫酸含量的增加,这种相互作用减弱。JM - 403表位的定位表明,它主要由一个或多个N - 未取代的葡糖胺单元主导,因为在硫酸乙酰肝素制剂中破坏或改变此类单元结构的处理(分别在pH 3.9时用HNO₂在N - 未取代的葡糖胺单元处切割以及用乙酸酐进行N - 乙酰化)会消除抗体结合。相反,在一种(D - 葡糖醛酸基 - 1,4 - N - 乙酰 - D - 葡糖胺基 - 1,4)多糖中可以通过生成N - 未取代的葡糖胺诱导免疫反应性。在JM - 403结合的硫酸乙酰肝素(来自人主动脉的制剂HS - II)中,经HNO₂(pH 3.9)处理后分子大小降低约3倍,证明了N - 未取代的葡糖胺的存在。基于用化学/酶修饰的多糖进行的酶联免疫吸附测定抑制试验,对JM - 403识别的表位进行进一步表征,结果表明一个或多个N - 硫酸化的葡糖胺单元始终存在,而L - 艾杜糖醛酸和O - 硫酸酯残基似乎会抑制JM - 403的反应性。得出的结论是,该表位包含一个或多个N - 未取代葡糖胺和D - 葡糖醛酸单元,并且位于由混合的N - 硫酸化和N - 乙酰化二糖单元组成的硫酸乙酰肝素链区域。